The technology addresses the limitations of previously available treatment methods. It is a less invasive cancer treatment method that does not directly damage healthy tissues and organs, unlike traditional radio- or chemotherapy. Instead, it works selectively on cancer cells that express a specific target antigen on their surface (e.g., CD19). This approach demonstrates significantly higher efficacy than antibody therapies by leveraging the high cytotoxic potential of natural effectors in the therapy—T lymphocytes.